{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:49:58Z","timestamp":1648550998487},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T00:00:00Z","timestamp":1465344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00115-016-0133-x","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T14:24:21Z","timestamp":1465395861000},"page":"303-307","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medikament\u00f6se r\u00fcckfallprophylaktische Behandlung der Alkoholabh\u00e4ngigkeit"],"prefix":"10.1007","volume":"88","author":[{"given":"J.","family":"Mutschler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Soyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"key":"133_CR1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA et\u00a0al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a\u00a0randomized controlled trial. JAMA 295:2003\u20132017","journal-title":"JAMA"},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton RF, Oroszi G, O\u2019Malley S et al (2008) An evaluation of \u03bc\u2011opioid receptor (oprm1) as a\u00a0predictor of naltrexone response in the treatment of alcohol dependence: Results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (combine) study. Arch Gen Psychiatry 65:135\u2013144","journal-title":"Arch Gen Psychiatry"},{"issue":"47","key":"133_CR3","first-page":"151","volume":"2014","author":"A Besirli","year":"2014","unstructured":"Besirli A, Esel E, \u00d6zsoy S, Turan T (2014) Hypothalamic-pituitary-adrenal axis response to oral naltrexone in alcoholics during early withdrawal. Pharmacopsychiatry 2014(47):151\u2013155","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"133_CR4","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/acer.12411.","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Del Re AC, Maisel NC, Finney JW (2014) A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 38(6):1481\u20131488. doi:10.1111\/acer.12411","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"133_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1708\/1139.12554","volume":"47","author":"R Brambilla","year":"2012","unstructured":"Brambilla R, Vigna-Taglianti F, Avanzi G, Faggiano F, Leone M (2012) Gamma-hydroxybutyrate (GHB) for mid\/long term treatment of alcohol dependence: a systematic review. Riv Psichiatr 47(4):269\u2013280. doi:10.1708\/1139.12554","journal-title":"Riv Psichiatr"},{"issue":"3","key":"133_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/alcalc\/agq017","volume":"45","author":"A Diehl","year":"2010","unstructured":"Diehl A, Ulmer L, Mutschler J, Herre H, Krumm B, Croissant B, Mann K, Kiefer F (2010) Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol 45(3):271\u2013277. doi:10.1093\/alcalc\/agq017","journal-title":"Alcohol Alcohol"},{"key":"133_CR7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","volume":"110","author":"K Donoghue","year":"2015","unstructured":"Donoghue K, Elzerbi C, Saunders R et al (2015) The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction 110:920\u2013930","journal-title":"Addiction"},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s00115-012-3633-3","volume":"84","author":"DM Gahr","year":"2012","unstructured":"Gahr DM, K\u00f6lle MA, Sch\u00f6nfeldt-Lecuona C (2012) R\u00fcckfallpr\u00e4vention bei Alkoholabh\u00e4ngigkeit: Acamprosat und Naltrexon als kombinierte pharmakologische Strategie. Nervenarzt 84:584\u2013589","journal-title":"Nervenarzt"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C et al (2014) Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 311:1889\u20131900","journal-title":"JAMA"},{"key":"133_CR10","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1038\/tp.2014.103","volume":"4","author":"VM Karpyak","year":"2014","unstructured":"Karpyak VM, Biernacka JM, Geske JR et al (2014) Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 4:e462. doi:10.1038\/tp.2014.103","journal-title":"Transl Psychiatry"},{"issue":"2","key":"133_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000083037","volume":"11","author":"F Kiefer","year":"2005","unstructured":"Kiefer F, Helwig H, Tarnaske T et\u00a0al (2005) Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 11(2):83\u201391","journal-title":"Eur Addict Res"},{"issue":"1","key":"133_CR12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biopsych.2005.11.023","volume":"60","author":"F Kiefer","year":"2006","unstructured":"Kiefer F, Jahn H, Otte C, Naber D, Wiedemann K (2006) Hypothalamic pituitary- adrenocortical axis activity: a target of pharmacological anti-craving treatment? Biol Psychiatr 60(1):74\u201376","journal-title":"Biol Psychiatr"},{"key":"133_CR13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"F Kiefer","year":"2003","unstructured":"Kiefer F, Jahn H, Tarnaske T et al (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of lcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92\u201399","journal-title":"Arch. Gen. Psychiatry"},{"key":"133_CR14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1369-1600.2007.00073.x","volume":"13","author":"F Kiefer","year":"2008","unstructured":"Kiefer F, Jim\u00e9nez-Arriero MA, Klein O, Diehl A, Rubio G (2008) Cloningers typology and treatment outcome in alcohol dependent subjects during pharmacotherapy with naltrexone. Addict Biol 13:124\u2013129","journal-title":"Addict Biol"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.2174\/138161210791516341","volume":"16","author":"F Kiefer","year":"2010","unstructured":"Kiefer F, Mann K (2010) Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des 16:2098\u20132102","journal-title":"Curr. Pharm. Des."},{"issue":"19","key":"133_CR16","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.2174\/138161210791516341","volume":"16","author":"F Kiefer","year":"2010","unstructured":"Kiefer F, Mann K (2010) Acamprosate: how, where, and for whom does it work? Curr Pharm Des 16(19):2098\u20132102","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"133_CR17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/alcalc\/agh093","volume":"36","author":"F Kiefer","year":"2004","unstructured":"Kiefer F, Wiedemann K (2004) Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol 36(6):542\u2013547","journal-title":"Alcohol Alcohol"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/tpj.2010.51","volume":"11","author":"F Kiefer","year":"2011","unstructured":"Kiefer F, Witt SH, Frank J et\u00a0al (2011) Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 11:368\u2013374","journal-title":"Pharmacogenomics J"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/138161210791516431","volume":"16","author":"H Krampe","year":"2010","unstructured":"Krampe H, Ehrenreich H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 16:2076\u20132090","journal-title":"Curr Pharm Des"},{"issue":"19","key":"133_CR20","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/138161210791516431","volume":"16","author":"H Krampe","year":"2010","unstructured":"Krampe H, Ehrenreich H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm 16(19):2076\u20132090","journal-title":"Curr Pharm"},{"key":"133_CR21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1530-0277.2006.00013.x","volume":"30","author":"H Krampe","year":"2006","unstructured":"Krampe H, Stawicki S, Wagner T et al (2006) Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 30:86\u201395","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"133_CR22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2515\/therapie\/2014038","volume":"69","author":"N Lesouef","year":"2014","unstructured":"Lesouef N, Bellet F, Mounier G, Beyens MN (2014) Efficacy of baclofen on abstinence and craving in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Therapie 69(5):427\u2013435","journal-title":"Therapie"},{"issue":"11","key":"133_CR23","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/npp.2015.101","volume":"40","author":"WR Lovallo","year":"2015","unstructured":"Lovallo WR, Enoch MA, Acheson A et al (2015) Cortisol stress response in men and women modulated differentially by the mu-Opioid receptor gene polymorphism OPRM1 A118G. Neuropsychopharmacology 40(11):2546\u20132554. doi:10.1038\/npp.2015.101","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"133_CR24","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/j.psyneuen.2012.04.006","volume":"37","author":"WR Lovallo","year":"2012","unstructured":"Lovallo WR, King AC, Farag NH et\u00a0al (2012) Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma family health patterns project. Psychoneuroendocrinology 37(12):1922\u20131928. doi:10.1016\/j.psyneuen.2012.04.006","journal-title":"Psychoneuroendocrinology"},{"key":"133_CR25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","volume":"108","author":"NC Maisel","year":"2013","unstructured":"Maisel NC, Blodgett JC, Wilbourne PL et al (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108:275\u2013293","journal-title":"Addiction"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","volume":"73","author":"K Mann","year":"2013","unstructured":"Mann K, Bladstr\u00f6m A, Torup L et al (2013) Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene. Biol Psychiatry 73:706\u2013713","journal-title":"Biol Psychiatry"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1530-0277.2008.00884.x","volume":"33","author":"K Mann","year":"2009","unstructured":"Mann K, Kiefer F, Smolka M et\u00a0al (2009) Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcoholism. Clin Exp Res 33:674\u2013683","journal-title":"Clin Exp Res"},{"key":"133_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12012","author":"K Mann","year":"2012","unstructured":"Mann K, Lemenager T, Hoffmann S et al (2012) Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. doi:10.1111\/adb.12012","journal-title":"Addict Biol"},{"issue":"11","key":"133_CR29","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1111\/acer.12546","volume":"38","author":"K Mann","year":"2014","unstructured":"Mann K, Vollst\u00e4dt-Klein S, Reinhard I et al (2014) Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res 38(11):2754\u20132762. doi:10.1111\/acer.12546","journal-title":"Alcohol Clin Exp Res"},{"key":"133_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00115-015-0022-8","volume":"87","author":"PDK Mann","year":"2015","unstructured":"Mann PDK, Hoch E, Batra A et\u00a0al (2015) Leitlinienorientierte Behandlung alkoholbezogener St\u00f6rungen. Nervenarzt 87:13\u201325","journal-title":"Nervenarzt"},{"key":"133_CR31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1517\/14656566.2014.876008","volume":"15","author":"CA M\u00fcller","year":"2014","unstructured":"M\u00fcller CA, Geisel O, Banas R, Heinz A (2014) Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother 15:471\u2013481","journal-title":"Expert Opin Pharmacother"},{"key":"133_CR32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/JCP.0b013e31825ddbe6","volume":"32","author":"J Mutschler","year":"2012","unstructured":"Mutschler J, Abbruzzese E, Witt SH et al (2012) Functional polymorphism of the dopamine \u03b2\u2011Hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J Clin Psychopharmacol 32:578\u2013580","journal-title":"J Clin Psychopharmacol"},{"key":"133_CR33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/00952990.2012.677889","volume":"39","author":"J Mutschler","year":"2013","unstructured":"Mutschler J, Eifler S, Dirican G et\u00a0al (2013) Functional social support within a medical supervised outpatient treatment program. Am J Drug Alcohol Abuse 39:44\u201349","journal-title":"Am J Drug Alcohol Abuse"},{"key":"133_CR34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-103592","author":"J Mutschler","year":"2016","unstructured":"Mutschler J, Grosshans M, Soyka M, R\u00f6sner S (2016) Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. doi:10.1055\/s-0042-103592","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"133_CR35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","volume":"72","author":"DW Oslin","year":"2015","unstructured":"Oslin DW, Leong SH, Lynch KG et\u00a0al (2015) Naltrexone vs placebo for the treatment of alcohol dependence: A randomized clinical trial. JAMA Psychiatry 72(5):430\u2013437","journal-title":"JAMA Psychiatry"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.pbb.2008.09.004","volume":"91","author":"LA Ray","year":"2009","unstructured":"Ray LA, Mackillop J, Leggio L et\u00a0al (2009) Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol Biochem Behav 91:489\u2013494","journal-title":"Pharmacol Biochem Behav"},{"key":"133_CR37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1590\/S1516-31802010000600014","volume":"128","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S et al (2010) Acamprosate for alcohol dependence. Sao Paulo Med J 128:379\u2013379","journal-title":"Sao Paulo Med J"},{"key":"133_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001867.pub3","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S et al (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. doi:10.1002\/14651858.CD001867.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"133_CR39","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","volume":"9","author":"MD Skinner","year":"2014","unstructured":"Skinner MD, Lahmek P, Pham H, Aubin H\u2011J (2014) Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS ONE 9(2):e87366","journal-title":"PLoS ONE"},{"key":"133_CR40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1017\/S1461145713001284","volume":"17","author":"M Soyka","year":"2014","unstructured":"Soyka M (2014) Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 17:675\u2013684","journal-title":"Int J Neuropsychopharmacol"},{"key":"133_CR41","doi-asserted-by":"crossref","unstructured":"Soyka M, Friede M, Schnitker J (2015) Comparing nalmefene and naltrexone in alcohol dependence: Are there any differences? Results from an indirect meta-analysis. Pharmacopsychiatry (in press)","DOI":"10.1055\/s-0035-1565184"},{"key":"133_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2015.11.003","author":"M Soyka","year":"2015","unstructured":"Soyka M, Mutschler J (2015) Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. Prog Neuropsychopharmacol Biol Psychiatry. doi:10.1016\/j.pnpbp.2015.11.003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"133_CR43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tips.2007.12.005","volume":"29","author":"R Spanagel","year":"2008","unstructured":"Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29(3):109\u2013115","journal-title":"Trends Pharmacol. Sci."},{"key":"133_CR44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","volume":"39","author":"R Spanagel","year":"2014","unstructured":"Spanagel R, Vengeliene V, Jandeleit B et al (2014) Acamprosate Produces Its Anti-Relapse Effects Via Calcium. Neuropsychopharmacology 39:783\u2013791","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"133_CR45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/npp.2013.264","volume":"39","author":"R Spanagel","year":"2014","unstructured":"Spanagel R, Vengeliene V, Jandeleit B et al (2014) Acamprosate produces ist anti-relapse effects via calcium. Neuropsychopharmacology 39(4):883\u2013891","journal-title":"Neuropsychopharmacology"},{"key":"133_CR46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","volume":"26","author":"JJ Suh","year":"2006","unstructured":"Suh JJ, Pettinati HM, Kampman KM, O\u2019Brien CP (2006) The status of disulfiram: A half of a century later. J\u00a0Clin Psychopharmacol 26:290\u2013302","journal-title":"J Clin Psychopharmacol"},{"key":"133_CR47","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W Brink van den","year":"2013","unstructured":"Brink W van den, Aubin H\u2011J, Bladstr\u00f6m A et al (2013) Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6\u2011month studies. Alcohol Alcohol 48:570\u2013578","journal-title":"Alcohol Alcohol"},{"key":"133_CR48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","volume":"28","author":"W Brink van den","year":"2014","unstructured":"Brink W van den, S\u00f8rensen P, Torup L et al (2014) Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1\u2011year, randomised controlled study. J Psychopharmacol 28:733\u2013744","journal-title":"J Psychopharmacol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-016-0133-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0133-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T11:18:20Z","timestamp":1568027900000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-016-0133-x"}},"subtitle":["Ergebnisse aktueller Metaanalysen"],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s00115-016-0133-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]}}}